GLP1R and obesity disorder: Among the emerging therapeutic options, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown potential in reducing adverse events in patients with type 2 diabetes [235] and obesity with preserved ejection fraction [236].